Easy, Accurate and Affordable Cancer Screening....Welcome to the Beacon Revolution!


Key Management
  • Donald F. Weber, CEO/President ​
  • Dr. Charlie Sthapanachai, MD, CLIA Lab Dir.
  • Monique Claudio, Lab Operations Manager

Key Advisors & Collaborators
  • Dr. Linda Greer, MD

         John C. Lincoln, Medical Dir., BHRC

  • Prof. Gordon Wishart, MB, ChB, MA, MD,     

         Medical Dir., Int'l HealthScreen Technologies

  • Dr. Barbara Marusiak, DHsc, MS, CRM

         Clinical Assoc. Professor, ASU

  • Mr. Dirk K. Beth

          Managing Director, Hyalescent Ventures

  • Mr. Jock Holliman
    Executive Chairman LipimetiX Development and Capstone Therapeutics

  • Mr. Thomas Curzon, JD

         Partner, Osborn Maledon, PA

Background & Experience

Beacon's management and world-class team of scientific, medical and business development collaborators & advisors have  over 190-years of combined experience & expertise in cancer biomarker research, assay development, medical device manufacturing, primary patient care & management, cancer  therapeutics,   global product   development, regulatory compliance, reimbursement, & intellectual property protection.

​​It All Starts With an Idea.

If early detection saves lives, then why with all  the billions of dollars being spent on patient education and awareness as to the life saving benefits of routine cancer screening are we seeing 100's of thousand of people still dying each year from cancer?  That question was the genesis behind Beacon Biomedical.

Right Test, Right People, Right Place, Right Time.

Right Test.  If our cancer screening tests are going to help save lives then they need to be designed in such a way as to optimize their adoption by doctors and patient alike...tests that are easy to administer for the doctors as well as being minimally invasive for the patients so as to avoid any undue pain, discomfort and anxiety often associated with existing cancer screening tests.  An easy, accurate and affordable test that uses a non-invasive sample of blood accomplishes this goal.

Right People.  We chose breast, colorectal and lung cancers as our initial focus due to their high annual mortalities. During our evaluation, some astonishing, yet obvious, facts emerged...65% of all the deaths  in the U.S. associated with breast and colorectal cancers are associated with the minority 1/3 of the men and women who are not compliant with recommended cancer screening.  As for lung cancer, 90%+ of all the deaths in the U.S. are associated with long-term smokers and ex-smokers.  As such, these are the patient populations we are targeting because these are the ones that will benefit the most from our tests ...tests that will promote compliance with and support access to  proven, life saving cancer screening procedures for breast (mammography), colorectal (colonoscopy) and lung (low dose CT Scans) cancers.

Right Place.  The right place for our tests is at the actual point-of-servcie.  This is where it matters the most because it is here where the traditionally noncompliant patients can be captured and evaluated as to their risk of having undiagnosed cancer, and where  proactive cancer healthcare discussions and follow-up monitoring, care & testing decisions can occur.

Right Time.  In order to provide the highest benefit possible, the test has to be easy to administer.  For our laboratory developed tests, a sample of blood can be drawn at the patient's well check visit with their doctor, and in the future we plan on having point-of-care tests, with actionable results within under 10-minutes.

Our Team

About Us